Jennison Associates LLC Buys 302,884 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Jennison Associates LLC increased its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 80.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 680,778 shares of the company's stock after acquiring an additional 302,884 shares during the period. Jennison Associates LLC owned about 1.15% of Twist Bioscience worth $31,636,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in TWST. AQR Capital Management LLC increased its stake in Twist Bioscience by 83.9% in the 2nd quarter. AQR Capital Management LLC now owns 61,428 shares of the company's stock valued at $3,027,000 after buying an additional 28,027 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Twist Bioscience by 3.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,064 shares of the company's stock valued at $1,531,000 after buying an additional 1,104 shares during the last quarter. SG Americas Securities LLC increased its stake in Twist Bioscience by 407.1% in the 3rd quarter. SG Americas Securities LLC now owns 10,958 shares of the company's stock valued at $495,000 after buying an additional 8,797 shares during the last quarter. CWM LLC increased its stake in Twist Bioscience by 141.9% in the 3rd quarter. CWM LLC now owns 5,894 shares of the company's stock valued at $266,000 after buying an additional 3,457 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in Twist Bioscience by 30.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 20,141 shares of the company's stock valued at $910,000 after buying an additional 4,661 shares during the last quarter.

Twist Bioscience Stock Performance

Shares of TWST stock traded down $1.40 during midday trading on Friday, hitting $52.30. 883,044 shares of the company were exchanged, compared to its average volume of 786,851. The firm has a market capitalization of $3.12 billion, a P/E ratio of -15.47 and a beta of 1.87. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.54 and a current ratio of 4.96. The firm's 50 day moving average price is $48.91 and its two-hundred day moving average price is $46.20. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business's revenue for the quarter was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.75) EPS. As a group, equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 5,200 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $256,620.00. Following the completion of the transaction, the chief executive officer now directly owns 667,318 shares in the company, valued at $32,932,143.30. This represents a 0.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Patrick John Finn sold 10,340 shares of the company's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $496,320.00. Following the transaction, the chief operating officer now owns 221,061 shares of the company's stock, valued at approximately $10,610,928. This represents a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 59,002 shares of company stock valued at $2,851,681 in the last quarter. Company insiders own 3.01% of the company's stock.

Analyst Upgrades and Downgrades

TWST has been the topic of several recent research reports. Robert W. Baird lifted their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a research note on Tuesday. Barclays lowered their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. JPMorgan Chase & Co. lifted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research report on Tuesday. Scotiabank lifted their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a "sector outperform" rating in a research report on Tuesday. Finally, TD Cowen reissued a "buy" rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.